Immune responses to rhinoviruses and asthma: Are we 3 steps closer to the door? - 05/09/20
Doi : 10.1016/j.jaci.2020.06.031
James E. Gern, MD ⁎ 
Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wis
∗Corresponding author: James E. Gern, MD, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Clinical Science Center-K4/918, 600 Highland Ave, Madison, WI 53792.Department of PediatricsSchool of Medicine and Public HealthUniversity of Wisconsin-MadisonClinical Science Center-K4/918600 Highland AveMadisonWI53792
Key words : Rhinovirus, asthma, age, T cells, allergy, omalizumab, inoculation, mouse
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: J. E. Gern is a paid consultant to AstraZeneca and Meissa Vaccines Inc, has stock options in Meissa Vaccines Inc, and has patents on production methods for rhinoviruses. |
© 2020
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 146 - N° 3
P. 513-514 - septembre 2020 Retour au numéro
Article précédent
- Pharmacogenomic biomarkers in allergy and immunology practice
- David A. Khan, Elizabeth J. Phillips
- Strengthening epithelial barriers through modulation of the histone code in allergic diseases—a novel approach for preventing the atopic march?
- Jörg Tost
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?